PepGen (PEPG) Expected to Announce Quarterly Earnings on Monday

PepGen (NASDAQ:PEPG) will likely be announcing its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

PepGen Trading Down 5.2%

NASDAQ PEPG opened at $6.44 on Monday. PepGen has a 12 month low of $0.88 and a 12 month high of $7.80. The firm has a market capitalization of $442.75 million, a PE ratio of -2.28 and a beta of 1.91. The business’s 50-day moving average price is $5.68 and its two-hundred day moving average price is $4.24.

Analysts Set New Price Targets

Several brokerages recently commented on PEPG. HC Wainwright upped their target price on PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, PepGen currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.75.

Institutional Trading of PepGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PEPG. Renaissance Technologies LLC raised its position in PepGen by 95.4% in the 4th quarter. Renaissance Technologies LLC now owns 147,900 shares of the company’s stock valued at $963,000 after buying an additional 72,200 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of PepGen by 309.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 135,216 shares of the company’s stock valued at $880,000 after purchasing an additional 102,210 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in shares of PepGen by 81.0% during the third quarter. ADAR1 Capital Management LLC now owns 36,842 shares of the company’s stock valued at $170,000 after purchasing an additional 16,490 shares in the last quarter. Two Sigma Investments LP boosted its holdings in PepGen by 45.1% during the third quarter. Two Sigma Investments LP now owns 92,493 shares of the company’s stock worth $427,000 after purchasing an additional 28,753 shares during the last quarter. Finally, UBS Group AG grew its position in PepGen by 1,714.5% in the 3rd quarter. UBS Group AG now owns 242,451 shares of the company’s stock worth $1,120,000 after purchasing an additional 229,089 shares in the last quarter. 58.01% of the stock is owned by institutional investors.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).